Personalis NeXT Platform: Precision Neoantigen Selection and Ultrasensitive MRD Detection

The Personalis NeXT Platform integrates deep tumor tissue genomic profiling with ultrasensitive plasma-based monitoring to support neoantigen-based immunotherapy development.

• ImmunoID NeXT delivers comprehensive immunogenomic profiling from tumor tissue, enabling accurate neoantigen selection through validated exome/transcriptome assays, and neoantigen predictions trained on immunopeptidomics data.
• NeXT Personal is a tumor-informed, plasma-based assay for detecting molecular residual disease, molecular response, and recurrence earlier, with longitudinal variant tracking for real-time insight into disease progression.
• Together, these assays provide a unified view from tumor to blood, enhancing precision oncology strategies.

Speakers:

Christelle Johnson

Director - Field Applications Scientist

Personalis Inc